Agomelatine (valdoxan) in treatment of endogenous depression in day patient department

Chernova E.V.

Psychiatric Hospital №13, Moscow, Russia

Kozhechkina O.V.

Psychiatric Hospital №13, Moscow, Russia

Ter-israelyan A.Yu.

Russian Peoples Friendship University, Moscow;
City Psychiatric Hospital №13, №71, Moscow

Medvedev V.E.

Russian Peoples Friendship University, Moscow

SPIN RSCI: 2814-4975
Scopus AuthorID: 55545252400
ResearcherID: AAH-1849-2020
ORCID: 0000-0001-8653-596X

Agomelatine (valdoxan) in treatment of endogenous depression in day patient department

Authors:

Chernova E.V., Kozhechkina O.V., Ter-israelyan A.Yu., Medvedev V.E.

More about the authors

Journal: S.S. Korsakov Journal of Neurology and Psychiatry. 2016;116(10): 43‑46

DOI: 10.17116/jnevro201611610143-46

Downloaded: 43

Download PDF (RU)

Contact the author

Table of contents

To cite this article:

Chernova EV, Kozhechkina OV, Ter-israelyan AYu, Medvedev VE. Agomelatine (valdoxan) in treatment of endogenous depression in day patient department. S.S. Korsakov Journal of Neurology and Psychiatry. 2016;116(10):43‑46. (In Russ.)
https://doi.org/10.17116/jnevro201611610143-46

Close metadata

Recommended articles:

Psychopharmacotherapy of mixed affective states in bipolar disorder. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(2):103-108

Willingness to expend effort for rewards in individuals at clinical high-risk for psychosis: a relationship with the severity and stability of negative symptoms. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(2):109-115

The relationship between the functional state of the brain and clinical and constitutional factors in schizophrenia. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(2):123-128

The association of polymorphisms of the serotonin transporter gene SLC6A4 with depression. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(2):135-139

The effect of insomnia on mild cognitive impairment in patients with vascular risks: results of a three-year longitudinal study. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(3-2):30-36

A perspective on the application of CRISPR/CAS9 genome editing system to study of molecular-genetic basis of mental disorders. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(3):27-33

Associations between components of metabolic syndrome and cognitive impairment in patients with schizophrenia. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(3):82-87

Validation of screening method based on EEG analysis for the risk assessment of psychiatric and behavioral disorders: a pilot study. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(3):88-96

A clinical case of the new-onset bipolar affective disorder in the postcovid period. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(3):125-129

Atypical antipsychotics in the treatment of depression in affective disorders and schizophrenia (using the aripiprazole model). S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(4):36-42

Objective. Naturalistic psychopharmacological study of efficacy and tolerability of agomelatine (valdoxan) in treatment of endogenous depressions (in the framework of schizophrenia, schizoaffective and bipolar disorder) in day patient department. Material and methods. Study sample consisted of 37 patient (59.4% female, mean age 41.6±3.7 years). Results and conclusion. CDS total score significantly reduced after 8 weeks of treatment 44.9% compared to baseline (р<0.001); HAM-D total score decreased on 51.3% compared to baseline (р<0.001). The proportion of responders at the 8th week of treatment was 54.1%. Agomelatine (valdoxan) had favorable safety profile. Follow-up study (up to 24 months) showed stable antidepressive effect and good tolerability profile of agomelatine (valdoxan). There was no withdrawal syndrome after treatment discontinuation.

Keywords:

depression

schizophrenia

bipolar affective disorder

agomelatine

Authors:

Chernova E.V.

Psychiatric Hospital №13, Moscow, Russia

Kozhechkina O.V.

Psychiatric Hospital №13, Moscow, Russia

Ter-israelyan A.Yu.

Russian Peoples Friendship University, Moscow;
City Psychiatric Hospital №13, №71, Moscow

Medvedev V.E.

Russian Peoples Friendship University, Moscow

SPIN RSCI: 2814-4975
Scopus AuthorID: 55545252400
ResearcherID: AAH-1849-2020
ORCID: 0000-0001-8653-596X

List of references:

Mosolov SN. (red.) Biologicheskie metody terapii psihicheskih rasstrojstv (dokazatel'naja medicina — klinicheskoj praktike). M.: Social'no-politicheskaja mysl'; 2012. (In Russ.).
Antohin EJu. Terapija tjazheloj rekurrentnoj depressii. Psihiatrija i psihofarmakoterapija. 2010;6. (In Russ.).
Gushanskaja EV, Frolova VI, Medvedev VJe. Terapija trevozhnoj depressii (opyt primenenija val'doksana). Zhurnal psihiatrii i psihofarmakoterapii im. P.B. Gannushkina. 2015;1:17-21. (In Russ.).
Ivanov SV. Val'doksan (agomelatin) pri terapii umerennyH i tjazhelyh depressij nepsihOticheskogo urovNja v ambulatOrnoj i goSpital'noj praktike (rezul'taty Rossijskogo mul'ticentrovogo issledovanija «HRONOS»). Psihiatrija i psihofarmakoterapija im. P.B. Gannushkina. 2009;6:14-17. (In Russ.).
Kuznechenkova LV. Jeffektivnost' i perenosimost' preparata val'doksan (agomelatin) pri depressivnyh sostojanijah v strukture razlichnyh nozologicheskih form. Psihiatrija i psihofarmakoterapija im. P.B. Gannushkina. 2012;4:18-21. (In Russ.).
Medvedev VJe. Terapija nepsihoticheskih depressij v ramkah involjucionnoj isterii (opyt primenenija val'doksana). Psihiatrija i psihofarmakoterapija im. P.B. Gannushkina. 2011;4:14-18. (In Russ.).
Medvedev VJe. Monoterapija disforicheskoj depressii val'doksanom. Psihiatrija i psihofarmakoterapija im. P.B. Gannushkina. 2016;1:20-23. (In Russ.).
Medvedev VJe, Gushanskaja EV, Ter-Israeljan AJu. Terapija depressij s javlenijami angedonii (opyt primenenija val'doksana). Psihiatrija i psihofarmakoterapija im. P.B. Gannushkina. 2014;3:45-49. (In Russ.).
Antohin EJu, Harina EA. Bipoljarnoe affektivnoe rasstrojstvo tipa II: osobennosti kliniki i vozmozhnosti kompleksnoj terapii, vkljuchajushhej val'doksan. Psihiatrija i psihofarmakoterapija im. P.B. Gannushkina. 2013;3:24-32. (In Russ.).
Petrova NN. K voprosu o terapii depressii u bol'nyh shizofreniej. Psihiatrija i psihofarmakoterapija im. P.B. Gannushkina. 2014;2:25-28. (In Russ.).
Poleckij VM, Kolmogorova VV, Kurkin SD, Darovskij O, Kushakovskaja E, Belousova N. Val'doksan v terapii postshizofrenicheskih depressij. Psihiatrija i psihofarmakoterapija im. P.B. Gannushkina. 2013;2:16-22. (In Russ.).
Medvedev VJe. Primenenie val'doksana (agomelatin) v kombinirovannoj terapii umerenno vyrazhennyh i tjazhelyh depressij nepsihoticheskogo urovnja. Zhurnal nevrologii i psihiatrii im. S.S. Korsakova. 2012;112:5:1:37-40. (In Russ.).
Medvedev VJe. Kombinirovannaja terapija depressii val'doksanom (agomelatin) i antipsihotikami. Psihiatrija i psihofarmakoterapija im. P.B. Gannushkina. 2012;2:20-23. (In Russ.).
Medvedev VJe. Vozmozhnost' kombinirovannoj terapii depressij melatoninergicheskim i triciklicheskimi antidepressantami. Psihiatrija i psihofarmakoterapija im. P.B. Gannushkina. 2012;1:53-56. (In Russ.).

Close metadata